Merck, Samsung Bioepis launch discounted Remicade alternative
Seoul
MERCK & CO and South Korea's Samsung Bioepis Co Ltd said on Monday that they have begun selling a less expensive alternative version of Johnson & Johnson's rheumatoid arthritis drug Remicade in the United States, a move that should accelerate price declines for the big-selling medicine.
The US and South Korean drugmakers said that they would sell their version, to be called Renflexis, at 35 per cent discount to the list price of J&J's top-selling medicine, or about US$735 for a 100 mg dose.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Another Cordlife director arrested amid CAD probe
Genting chairman says open to casino resort development in UAE
Spotify sued over alleged unpaid royalties
Under Armour forecasts downbeat annual sales and profit, shares slump
J&J to acquire Proteologix for US$850 million
Watches of Switzerland sees used watch sales double